The hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer

Chizu Kameda, Haruo Tanaka, Akio Yamasaki, Masafumi Nakamura, Kenichiro Koga, Norihiro Sato, Makoto Kubo, Syoji Kuroki, Masao Tanaka, Mitsuo Katano

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Understanding the expression patterns of estrogen receptor- α(ERα)is essential for determining therapeutic strategies for patients with breast cancer. The prognosis of patients with ERα-negative breast cancer is still poor. We have previously shown that Hedgehog(Hh)signaling is constitutively activated in breast cancer and that Hh signaling could be a new therapeutic target. Therefore, in this study, whether or not Hh signaling could be utilized as a therapeutic target for patients with ERα-negative breast cancer was examined. For this purpose, three ERα-negative breast cancer cell lines were used in which Hh pathway- related molecules such as the ligand Patchedl and the transcriptional factor Glil as target cells are expressed. Cyclopamine, an inhibitor of the Hh pathway, significantly suppressed both the cell proliferation and invasion ability of these cancer cells. In addition, the knockdown of Glil by RNA interference in these cells also significantly reduced both cell proliferation and invasion ability. Since our previous data have shown a constitutive activation of the Hh pathway in surgically-resected ERα-negative breast cancer specimens, the Hh pathway, especially Glil, may be a useful therapeutic target for patients with ERα-negative breast cancer.

Original languageEnglish
Pages (from-to)871-880
Number of pages10
JournalAnticancer research
Volume29
Issue number3
Publication statusPublished - Mar 1 2009

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kameda, C., Tanaka, H., Yamasaki, A., Nakamura, M., Koga, K., Sato, N., ... Katano, M. (2009). The hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. Anticancer research, 29(3), 871-880.